I have been traveling and neglecting my duties at Secondhand Smoke. Whilst gone, readers alerted me to the pathetic excuse given by the New York Times for not reporting the amniotic fluid stem cell breakthrough. Its reporter, Nicolas Wade, claimed he didn’t report it because the study was merely a “minor” matter. Yet, less important ESCR stories have been prominently reported in the Gray Lady. Moreover the story was front page news in the Washington Post, San Francisco Chronicle, and other MSM outlets. Hmmm. Could it be—bias?
Not to worry. I may have been asleep at the switch but Michael Fumento was on the case. He also chides Newsweek for reporting that human trials with placental stem cells will not happen for years, when apparently, at least one is already under way. Way to go, Michael!
Dear Reader,
Can I be direct with you?
War abroad. Socialists on the rise. AI upending human life. Endless uproar online. The modern attention economy doesn’t want readers — it wants users enslaved to the tyranny of the present.
First Things is the antidote: literary excellence, timeless truths, and a fixed point of reference in a culture that has lost its bearings.
But we can’t do it without readers like you.
Our goal: Raise $150,000 by November 1 to sustain First Things in the year ahead.
Your gift anchors readers in the permanent things.
Make your Fall Campaign gift now using the button below.
If you have any questions or would like more information, please contact Giovanni Del Piero, Director of the Editor’s Circle, at gdelpiero@firstthings.com or 212-627-1985.
YOU MIGHT ALSO LIKE
The Church in the Age of Therapy
In 1966, Philip Rieff wrote in The Triumph of the Therapeutic that “Religious man was born to…
Canada’s Deadliest Blind Spot
On September 20, the Daily Mail ran a story with the provocative headline, “Our 83-year-old Christian grandmother…
The Faithful Joy of Dolly Parton and Fulton Sheen
Dolly Parton and Fulton Sheen seem to have had little in common. She favored rhinestones; he wore…
